Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Uveal Melanoma 4Melanoma 2Sarcoma, Clear Cell 1Sarcoma 1Neoplasm Metastasis 1

Interventions

Ipilimumab 17Nivolumab 15incomplete Freund's adjuvant 8Cyclophosphamide 7CTLA-4 Antigen 7pembrolizumab 6Ranibizumab 6sargramostim 5Radiosurgery 5Blood Specimen Collection 5tebentafusp 4Temozolomide 4Surveys and Questionnaires 4Magnetic Resonance Spectroscopy 4MART-1 Antigen 4Granulocyte-Macrophage Colony-Stimulating Factor 4Biopsy 4Bevacizumab 4fludarabine phosphate 3fludarabine 3aflibercept 3Thalidomide 3Sunitinib 3Specimen Handling 3MAGEA3 protein, human 3Interleukin-2 3130-nm albumin-bound paclitaxel 3relatlimab 2olaparib 2montanide ISA 51 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Uveal Melanoma × tebentafusp × Clear all
NCT07276386 2026-03-31

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
18 enrolled
Dermatologic

Uveal Melanoma

NCT06070012 2026-02-27

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

University of Pittsburgh

Phase 2 Recruiting
44 enrolled
Dermatologic

Uveal Melanoma

NCT06627244 2026-02-23

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

University of Miami

Phase 2 Recruiting
30 enrolled
Dermatologic

Uveal Melanoma

NCT05315258 2025-07-17

TebeMRD

University of Oxford

Phase 2 Active not recruiting
850 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡